Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Super DC Vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Super DC Vaccine overview
The therapeutic candidate is under development for the treatment of advanced solid tumors. It comprises of dendritic cells and is administered through parenteral route.
Shanghai Cell Therapy Group overview
Shanghai Cell Therapy Group, is a biotechnology company that develops tumour immune cell therapy treatments. The company is headquartered in China.
For a complete picture of Super DC Vaccine’s drug-specific PTSR and LoA scores, buy the report here.